Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moEMVERM (mebendazole) by Johnson & Johnson is mebendazole, a benzimidazole, is an anthelmintic drug [see microbiology (12. Approved for older with gastrointestinal infections caused by: ancylostoma duodenale (hookworm), ascaris lumbricoides (roundworm), enterobius vermicularis (pinworm) and 2 more indications. First approved in 1995.
Drug data last refreshed 3d ago
Mebendazole, a benzimidazole, is an anthelmintic drug [see Microbiology (12.4)] .
Worked on EMVERM at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
A Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Participants
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
A Safety Study of Mebendazole in Children 2 to 10 Years of Age
Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo